fda glp-1 safety alert october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Pharmacovigilance analysis of neurological adverse

transparency between your weight loss therapy team and your surgical team reduces complications and speeds your safe return to treatment after healing

Enhancing the neuroprotection potential of edaravone in transient global ischemia treatment with glutathione- (GSH-) conjugated poly(methacrylic acid) nanogel as a promising carrier for targeted brain drug delivery

In cases where reflux persists despite these interventions, dose reduction or slower titration can help

Researchers interested in supporting skin health during rapid weight loss may want to explore peptides for anti-aging and collagen-supporting interventions that promote elastin and collagen synthesis

A real-world analysis of approximately 8,000 patients from the Cleveland Clinic found considerably less weight regain than clinical trial data would predict largely because many real-world patients transition to another weight-loss agent, restart semaglutide, or maintain structured lifestyle interventions after stopping

If youre seeing a lot of female clients in these categories, B12 is worth having in your toolkit and worth discussing proactively rather than waiting for them to bring it up